A scaffold vaccine to promote tumor antigen cross-presentation via sustained toll-like receptor-2 (TLR2) activation

• Published in: Bioactive materials Vol. 37; pp. 315 - 330
• Main Authors: Xie, Daping, Han, Congwei, Chen, Chonghao, Liao, Zhencheng, Campos de Souza, Senio, Niu, Yiming, Mano, João F., Dong, Lei, Wang, Chunming
• Format: Journal Article
• Language: English
• Published: China Elsevier B.V 01.07.2024; KeAi Publishing Communications Ltd; KeAi Publishing; KeAi Communications Co., Ltd
• Subjects: Adjuvants; Antigen (tumor-associated); Antigen presentation; Antigen-presenting cells; Antigens; Cancer; Cancer therapies; Cancer vaccines; CD8 antigen; Cell activation; Chemical synthesis; Colorectal carcinoma; Cross-presentation; Cytokines; Cytotoxicity; Dendritic cells; Effectiveness; Hyaluronic acid; Hydrophobicity; Lung cancer; Lymphocytes; Lymphocytes T; Major histocompatibility complex; Medical research; Metastases; Molecular weight; Ovalbumin; Polysaccharide; Polysaccharides; Reactive oxygen species; Scaffold vaccine; Scaffolds; TLR2 agonist; TLR2 protein; Toll-like receptors; Transgenic mice; Tumors; Vaccines; United States > US; China; Cross-presentation; Reactive oxygen species; Scaffold vaccine; TLR2 agonist; Polysaccharide

Cancer vaccination holds great promise for cancer treatment, but its effectiveness is hindered by suboptimal activation of CD8+ cytotoxic T lymphocytes, which are potent effectors to mediate anti-tumor immune responses. A possible solution is to switch antigen-presenting cells to present tumor antig...